By Hendra Lukman 
Researchers at the Princeton University Branch of the Ludwig Institute for Cancer Research have illuminated a sophisticated mechanism by which a molecule derived from vitamin A, known as all-trans retinoic acid (ATRA), can actively undermine the body’s natural defenses against cancer. This discovery, detailed across two groundbreaking scientific publications, not only clarifies long-standing ambiguities surrounding the dual nature of vitamin A metabolites but also heralds the development of the first experimental drugs designed to counteract this immune suppression. The findings have profound implications for the future of cancer immunotherapy, particularly for promising treatments like dendritic cell (DC) vaccines.
Unmasking ATRA’s Immune Sabotage
For decades, retinoids, the group of compounds to which ATRA belongs, have been a source of scientific intrigue due to their multifaceted effects on health and disease. While known for their essential roles in vision, cell growth, and differentiation, their involvement in cancer has presented a complex paradox. Some studies have suggested anti-cancer properties, while others have indicated that high vitamin A intake might correlate with increased cancer risk. The latest research from the Ludwig Institute, led by renowned molecular biologist Yibin Kang, offers a critical piece of this puzzle, revealing how ATRA can actively suppress anti-tumor immune responses.
The first study, published in the prestigious journal Nature Immunology, was co-led by Kang and graduate student Cao Fang. Their investigation pinpointed a crucial role for ATRA produced by dendritic cells (DCs), the master orchestrators of the adaptive immune system. These key immune cells are responsible for capturing antigens—molecular flags that signal the presence of threats—and presenting them to T cells, thereby initiating an immune attack. However, Kang and Fang’s team discovered that ATRA can reprogram DCs themselves, inducing a state of immune tolerance towards tumors. This phenomenon significantly hampers the effectiveness of DC-based cancer vaccines, a sophisticated form of immunotherapy designed to train the patient’s immune system to recognize and eliminate cancerous cells.
A Novel Therapeutic Avenue: Inhibiting Retinoid Signaling
The implications of this discovery extend beyond understanding the problem; they provide a clear path toward a solution. The researchers not only identified how ATRA disrupts immune responses but also successfully developed and pre-clinically tested an experimental drug, code-named KyA33. This compound is designed to block ATRA production within both cancer cells and DCs. In animal studies, KyA33 demonstrated a remarkable ability to enhance the efficacy of DC vaccines. More excitingly, it also showed potential as a standalone immunotherapy, capable of mounting an anti-cancer attack even without the aid of a vaccine.
Complementing these findings, a second study, published in iScience, was spearheaded by former Kang lab graduate student Mark Esposito. This research focused on the broader challenge of designing drugs that can effectively inhibit ATRA production and, by extension, disable the entire retinoid signaling pathway. Despite over a century of scientific inquiry into retinoids, attempts to create safe and effective drugs that block their signaling have consistently met with failure. The iScience study details a sophisticated approach that combined cutting-edge computational modeling with large-scale drug screening. This innovative methodology laid the groundwork for the development of KyA33, marking a significant breakthrough in targeting a cellular pathway that has long resisted pharmacological intervention.
The Broader Impact on Cancer Immunotherapy
"Taken together, our findings reveal the broad influence retinoic acid has in attenuating vitally important immune responses to cancer," stated Dr. Yibin Kang, a member of the Ludwig Institute for Cancer Research and a professor at Princeton University. "In exploring this phenomenon, we also solved a longstanding challenge in pharmacology by developing safe and selective inhibitors of retinoic acid signaling and established preclinical proof of concept for their use in cancer immunotherapy."
The research sheds light on how cancer cells can exploit the body’s own molecular machinery to evade immune detection. ATRA is synthesized by an enzyme known as ALDH1a3, which is frequently found at elevated levels in various human cancer cells. A related enzyme, ALDH1a2, plays a similar role in producing ATRA within specific subsets of DCs. Once generated, ATRA binds to a nuclear receptor within cells, initiating a cascade of molecular events that alter gene activity. This signaling pathway is known to promote the development of regulatory T cells (Tregs) in the gut, which are crucial for preventing autoimmune reactions. However, the precise impact of ATRA on DCs themselves remained largely enigmatic until this recent research.
Dendritic Cells: The Frontline Defenders Under Siege
Dendritic cells are the sentinels of the immune system, constantly patrolling the body for any signs of danger, including infections and nascent tumors. Upon detecting such threats, they process fragments of abnormal proteins—antigens—and display them to T cells. This presentation is the critical first step in mobilizing T cells to seek out and destroy diseased or cancerous cells.
Dendritic cell vaccines represent a sophisticated application of this immune principle. The process involves collecting immature immune cells from a patient’s blood, culturing them in the laboratory, and exposing them to specific tumor antigens extracted from the patient’s own cancer. These "primed" DCs are then reintroduced into the patient with the aim of igniting a robust and targeted anti-tumor immune response. Despite advancements in identifying suitable cancer antigens, these vaccines have often fallen short of their therapeutic promise in clinical trials. Fang, Kang, and their colleagues, including Esposito and Princeton Branch Director Joshua Rabinowitz, embarked on a mission to unravel the reasons behind this suboptimal performance.
The Paradox of Vitamin A: From Ally to Adversary
"We discovered that under conditions commonly employed to produce DC vaccines, differentiating dendritic cells begin expressing ALDH1a2, producing high levels of retinoic acid," explained Fang. "The nuclear signaling pathway it activates then suppresses DC maturation, diminishing the ability of these cells to trigger anti-tumor immunity. This previously unknown mechanism likely contributes to the largely suboptimal performance of DC and other cancer vaccines that has been repeatedly seen in clinical trials."
The detrimental effects of ATRA extend beyond its impact on DCs. The research also revealed that ATRA released by DCs can promote the development of a specific type of macrophage that is less effective at combating cancer. As these less functional macrophages accumulate in the tumor microenvironment, they further dilute the impact of any anti-cancer immune cells, exacerbating the overall suppression of the immune response.
Restoring Immune Potency with KyA33
The researchers demonstrated that by inhibiting ALDH1a2, either through genetic manipulation or with the experimental drug KyA33, they could restore the maturation of DCs and their capacity to activate potent immune defenses. In preclinical models of melanoma in mice, DC vaccines produced in the presence of KyA33 elicited strong, targeted immune responses. These responses were associated with delayed tumor development and a significant slowing of cancer progression. Furthermore, when administered directly to mice, KyA33 itself acted as a potent immunotherapy, reducing tumor growth by stimulating the immune system to mount an attack.
The development of inhibitors targeting ALDH1a2 and ALDH1a3 represents a monumental scientific achievement. The retinoic acid pathway was the first nuclear receptor signaling pathway to be discovered, over a century ago, yet it remained the only one that had not been successfully targeted by therapeutic drugs. The iScience study meticulously outlines the computational and experimental strategies employed to surmount this long-standing hurdle.
The new compounds developed by Esposito and Kang’s team finally provide a mechanistic explanation for the perplexing paradox surrounding vitamin A and cancer. Laboratory experiments have shown that ATRA can induce cancer cells to cease dividing or even self-destruct, fostering the belief that vitamin A possesses anti-cancer properties. Conversely, large-scale clinical trials and epidemiological data have indicated that high vitamin A intake can increase the risk of certain cancers (and cardiovascular disease) and elevate mortality rates. Moreover, elevated levels of ALDH1A enzymes in tumors are consistently linked to poorer survival outcomes across a wide spectrum of cancers. Previous attempts to disentangle the diverse functions of ALDH1A enzymes from their role in ATRA production had largely proven unsuccessful.
Cancer’s Exploitation of ATRA Explained
"Our study reveals the mechanistic basis for this paradox," explained Esposito. "We’ve shown that ALDH1a3 is overexpressed in diverse cancers to generate retinoic acid, but that cancer cells lose their responsiveness to retinoid receptor signaling, avoiding its potential anti-proliferative or differentiating effects. This explains, in part, the paradox of vitamin A’s effects on cancer growth."
The research further elucidates that ATRA’s primary impact is not on the cancer cells themselves, but on the immune environment surrounding the tumor. By accumulating within the tumor microenvironment, ATRA effectively dampens immune responses, including the activity of T cells that are programmed to target cancer. To validate this, the team demonstrated that inhibitors of ALDH1a3 successfully stimulated robust immune attacks against tumors in mouse models, underscoring their considerable potential as powerful immunotherapies.
The Dawn of a New Era in Cancer Treatment
"By developing candidate drugs that safely and specifically inhibit nuclear signaling through the retinoic acid pathway, we are paving the way for a novel therapeutic approach to cancer," Dr. Kang concluded.
Building on these pivotal discoveries, Esposito and Kang have co-founded a biotechnology company named Kayothera. The company is dedicated to advancing these ALDH1A inhibitors into human clinical trials, with the ultimate goal of developing treatments not only for various cancers but also for other diseases influenced by retinoid signaling, such as diabetes and cardiovascular disease. This work represents a significant leap forward in harnessing the body’s own immune system to combat cancer and a testament to the power of persistent scientific inquiry.
Funding and Research Support
The Nature Immunology study received crucial support from the Ludwig Institute for Cancer Research, the Brewster Foundation, the Susan Komen Foundation, Metavivor Breast Cancer Research, the Breast Cancer Research Foundation, and the American Cancer Society.
The iScience study was also generously supported by the Ludwig Institute for Cancer Research, the New Jersey Health Foundation, the Brewster Foundation, the Susan Komen Foundation, the Breast Cancer Research Foundation, the American Cancer Society, and the National Science Foundation.
Dr. Yibin Kang is a distinguished member of the Princeton Branch of the Ludwig Institute for Cancer Research, holds the Warner-Lambert/Parke-Davis Professorship of Molecular Biology at Princeton University, and serves as an Associate Director at Rutgers Cancer Institute of New Jersey.
